Cerebrospinal fluid pleocytosis in children in the era of bacterial conjugate vaccines: Distinguishing the child with bacterial and aseptic meningitis

Pediatric Emergency Care

Volumn 25, Issue 2, 2009, Pages 112-120

  Nigrovic, Lise E ^a   Malley, Richard ^a   Kuppermann, Nathan ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aseptic meningitis; Bacterial meningitis; CSF pleocytosis; Pneumococcal conjugate vaccine; Prediction model

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; STREPTOCOCCUS VACCINE;

ANTIBIOTIC THERAPY; ASEPTIC MENINGITIS; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CIRCULATION DISORDER; CEREBROSPINAL FLUID CULTURE; CHILD; CLINICAL DECISION MAKING; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HERPES ZOSTER ENCEPHALITIS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LATEX AGGLUTINATION TEST; LEUKOCYTE COUNT; LUMBAR PUNCTURE; NEISSERIA MENINGITIDIS; PLEOCYTOSIS; PREVALENCE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; VACCINATION; VALIDATION STUDY;

BACTERIAL VACCINES; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKOCYTOSIS; MENINGITIS, ASEPTIC; MENINGITIS, BACTERIAL;

EID: 66249140970     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e318196faeb     Document Type: Review

References (80)

1. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccine. Pediatrics. 1988;81(6):908-911.
2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl JMed. 1997;337(14):970-976.
3. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000; 106(2 pt 1):362-366.
4. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100-121.
5. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-poly saccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746.
6. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 pt 1):443-449.
7. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14): 1668-1674.
8. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14): 1455-1463.
9. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792.
10. Steenhoff AP, Shah SS, Ratner AJ, et al. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42(7):907-914.
11. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26(6):461-467.
12. Dubos F, Moulin F, Raymond J, et al. Distinction between bacterial and aseptic meningitis in children: refinement of a clinical decision rule [in French]. Arch Pediatr. 2007;14(5):434-438.
13. Nigrovic LE, Kuppermann N, Macias CG, et al. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA. 2007;297(1):52-60.
14. Nigrovic LE, Kuppermann N, Malley R. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med. 2008;15(6):522-528.
15. Oostenbrink R, Moons KG, Theunissen CC, et al. Signs of meningeal irritation at the emergency department: how often bacterial meningitis? Pediatr Emerg Care. 2001;17(3):161-164.
16. Valmari P, Peltola H, Ruuskanen O, et al. Childhood bacterial meningitis: initial symptoms and signs related to age, and reasons for consulting a physician. Eur J Pediatr. 1987;146(5):515-518.
17. Barnett ED, Bauchner H, Teele DW, et al. Serious bacterial infections in febrile infants and children selected for lumbar puncture. Pediatr Infect Dis J. 1994;13(11):950-953.
18. Levy M, Wong E, Fried D. Diseases that mimic meningitis. Analysis of 650 lumbar punctures. Clin Pediatr (Phila). 1990;29(5):254-255, 259-261.
19. Mehl AL. Interpretation of traumatic lumbar puncture. Predictive value in the presence of meningitis. Clin Pediatr (Phila). 1986;25(11):575-577.
20. Bonadio WA, Smith DS, Goddard S, et al. Distinguishing cerebrospinal fluid abnormalities in children with bacterial meningitis and traumatic lumbar puncture. J Infect Dis. 1990;162(1):251-254.
21. Mazor SS, McNulty JE, Roosevelt GE. Interpretation of traumatic lumbar punctures: who can go home? [see comment][erratum appears in Pediatrics. 2003;1 11(5): 1127]. Pediatrics. 2003;111(3):525-528.
22. Anbar RD. Pitfalls in interpretation of traumatic lumbar puncture formula. Am J Dis Child. 1986;140(8):737-738.
23. Bonadio WA. Interpreting the traumatic lumbar puncture. Contemp Pediatr. 1989;6:106-116.
24. Baxter AL, Fisher RG, Burke BL, et al. Local anesthetic and stylet styles: factors associated with resident lumbar puncture success. Pediatrics. 2006; 117(3):876-881.
25. Nigrovic LE, Kuppermann N, Neuman MI. Risk factors for traumatic or unsuccessful lumbar punctures in children. Ann Emerg Med. 2007;49(6):762-771.
26. Neuman MI, Tolford S, Harper MB. Test characteristics and interpretation of cerebrospinal fluid Gram stain in children. Pediatr Infect Dis J. 2008;27:309-313.
27. Freedman SB, Marrocco A, Pirie J, et al. Predictors of bacterial meningitis in the era after Haemophilus influenzae. Arch Pediatr Adolesc Med. 2001;155(12):1301-1306.
28. Sato Y, Ohta Y, Honda Y, et al. Diagnostic value of atypical lymphocytes in cerebrospinal fluid from adults with enteroviral meningitis. J Neurol. 1998;245(9):598-602.
29. Baker R, Lenane A. The predictive value of cerebrospinal fluid differential cytology in meningitis. Pediatr Infect Dis J. 1989;8(5):329-330.
30. Berkley J, Mwangi I, Ngetsa C, et al. Diagnosis of acute bacterial meningitis at a district hospital in sub-Saharan Africa. Lancet. 2001;357:1753-1757.
31. Dunbar S, Eason R, Musher D, et al. Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis. J Clin Microbiol. 1998;36(6): 1617-1620.
32. Negrini B, Kelleher KJ, Wald ER. Cerebrospinal fluid findings in aseptic versus bacterial meningitis. Pediatrics. 2000;105(2): 316-319.
33. Leib S, Bosacci R, Gratzl O, et al. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis. 1999;29(1):69-74.
34. Schwarz S, Bertram M, Schwab S, et al. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med. 2000;28(6): 1828-1832.
35. Gendrel D, Raymond J, Assicot M, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis. 1997;24:1240-1242.
36. Viallon A, Zeni F, Lambert C, et al. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis. 1999;28:1313-1316.
37. Dubos F, Moulin F, Gajdos V, et al. Serum procalcitonin and other biologic markers to distinguish between bacterial and aseptic meningitis. J Pediatr. 2006;149(1):72-76.
38. Hansson L, Axelsson G, Linne T, et al. Serum C-reactive protein in the differential diagnosis of acute meningitis. Scand J Infect Dis. 1993; 25(5):625-630.
39. Lembo R, Marchant C. Acute phase reactants and risk of bacterial meningitis among febrile infants and children. Ann Emerg Med. 1991;20(1):36-40.
40. Korczowski B, Bijos A, Rybak A. Procalcitonin in diagnosis of purulent and aseptic meningitis in children [in Polish]. Pol Merkur Lekarski. 2000;9(53):755-757.
41. Dubos F, Korczowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med. 2008;162(12):1 157-1163.
42. Dulkerian S, Kilpatrick L, AT C, et al. Cytokine elevation in infants with bacterial and aseptic meningitis. J Pediatr. 1995;126(6):872-876.
43. López-Cortés L, Marquez-Arbizu R, Jimenez-Jimenez L, et al. Cerebrospinal fluid tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 as diagnostic markers of cerebrospinal fluid infection in neurosurgical patients. Crit Care Med. 2000; 28(1):215-219.
44. Graham AK, Murdoch DR. Association between cerebrospinal fluid pleocytosis and enteroviral meningitis. J Clin Microbiol. 2005; 43(3):1491.
45. Lee BE, Davies HD. Aseptic meningitis. Curr Opin Infect Dis. 2007;20(3):272-277.
46. Ramers C, Billman G, Hartin M, et al. Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management. JAMA. 2000;283(20):2680-2685.
47. King RL, Lorch SA, Cohen DM, et al. Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger. Pediatrics. 2007;120(3):489-496.
48. Jansen GJ, Mooibroek M, Idema J, et al. Rapid identification of bacteria in blood cultures by using fluorescently labeled oligonucleotide probes. J Clin Microbiol. 2000;38(2):814-817.
49. Poppert S, Essig A, Stoehr B, et al. Rapid diagnosis of bacterial meningitis by real-time PCR and fluorescence in situ hybridization. J Clin Microbiol. 2005;43(7):3390-3397.
50. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9): 1267-1284.
51. Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J. 1988; 7(3): 160-164.
52. Congeni BL, Bradley J, Hammerschlag MR. Safety and efficacy of once daily ceftriaxone for the treatment of bacterial meningitis. Pediatr Infect Dis. 1986;5(3):293-297.
53. Spanos A, Harrell FE Jr, Durack DT. Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA. 1989;262(19):2700-2707.
54. Bonsu BK, Harper MB. Differentiating acute bacterial meningitis from acute viral meningitis among children with cerebrospinal fluid pleocytosis: a multivariable regression model. Pediatr Infect Dis J. 2004;23(6):511-517.
55. Oostenbrink R, Moons KG, Donders AR, et al. Prediction of bacterial meningitis in children with meningeal signs: reduction of lumbar punctures. Acta Paediatr. 2001;90(6):611-617.
56. Baty V Viel JF, Schuhmacher H, et al. Prospective validation of a diagnosis model as an aid to therapeutic decision-making in acute meningitis. Eur J Clin Microbiol Infect Dis. 2000; 19:422-426.
57. Oostenbrink R, Moons KG, Twijnstra MJ, et al. Children with meningeal signs: predicting who needs empiric antibiotic treatment. Arch Pediatr Adolesc Med. 2002;156(12): 1189-1194.
58. Bonsu BK, Harper MB. Explanation of mathematical model. Pediatr Infect Dis J. 2004;23(9):893.
59. Oostenbrink R, Moons KG, Derksen-Lubsen AG, et al. A diagnostic decision rule for management of children with meningeal signs. Eur J Epidemiol. 2004;19(2):109-116.
60. Nigrovic LE, Kuppermann N, Malley R. Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-Haemophilus influenzae era. Pediatrics. 2002;1 10(4):712-719.
61. Oostenbrink R, Moll HA, Moons KG, et al. Predictive model for childhood meningitis. Pediatr Infect Dis J. 2004;23(1 1):1070-1071.
62. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000; 19(3): 187-195.
63. Fine AM, Nigrovic LE, Reis BY, et al. Linking surveillance to action: incorporation of real-time regional data into a medical decision rule. J Am Med Inform Assoc. 2007;14(2):206-211.
64. Dubos F, Lamotte B, Bibi-Triki F, et al. Clinical decision rules to distinguish between bacterial and aseptic meningitis. Arch Dis Child. 2006;91:647-650.
65. Pierart J, LePage P. Utilite du BBacterial Meningitis Score (BMS)[ dans le Diagnostic Differentiel des Meningites Baceteriennes et Virales. Rev Med Liege. 2006;61(1):1-5.
66. Dubos F, De la Rocque F, Levy C, et al. Sensitivity of the bacterial meningitis score in 889 children with bacterial meningitis. J Pediatr. 2008;152(3):378-382.
67. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144(3):201-209.
68. Dalton HP, Allison MJ. Modification of laboratory results by partial treatment of bacterial meningitis. Am J Clin Pathol. 1968; 49(3):410-413.
69. Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics. 2001;108(5):1 169-1174.
70. Maxson S, Lewno MJ, Schutze GE. Clinical usefulness of cerebrospinal fluid bacterial antigen studies. J Pediatr. 1994; 125(2):235-238.
71. Perkins MD, Mirrett S, Reller LB. Rapid bacterial antigen detection is not clinically useful. J Clin Microbiol. 1995;33(6):1486-1491.
72. Tarafdar K, Rao S, Recco RA, et al. Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culture-negative meningitis. Clin Infect Dis. 2001;33(3):406-408.
73. Nigrovic LE, Kuppermann N, McAdam AJ, et al. Cerebrospinal latex agglutination fails to contribute to the microbiologic diagnosis of pretreated children with meningitis. Pediatr Infect Dis J. 2004; 23(8):786-788.
74. Winkelstein JA. The influence of partial treatment with penicillin on the diagnosis of bacterial meningitis. J Pediatr. 1970;77(4): 619-624.
75. Davis SD, Hill HR, Feigl P, et al. Partial antibiotic therapy in Haemophilus influenzae meningitis. Its effect on cerebrospinal fluid abnormalities. Am J Dis Child. 1975;129(7):802-807.
76. Kaplan SL, Smith EO, Wills C, et al. Association between preadmission oral antibiotic therapy and cerebrospinal fluid findings and sequelae caused by Haemophilus influenzae type b meningitis. Pediatr Infect Dis. 1986;5(6):626-632.
77. Converse GM, Gwaltney JM Jr, Strassburg DA, et al. Alteration of cerebrospinal fluid findings by partial treatment of bacterial meningitis. J Pediatr. 1973;83(2):220-225.
78. Nigrovic LE, Malley R, Macias CG, et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics. 2008;122:726-730.
79. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468-472.
80. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to nonYpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9): 1346-1354.